The Riverside Co. has sold Global Orthopaedic Technologies to Corin Orthopaedic Holdings Ltd., representing the Cleveland-based private equity firm’s fourth exit in the past 12 months in the Asia-Pacific region. Riverside, in partnership with Global Orthopaedic’s CEO Andrew Fox-Smith and COO Duncan Lilley, led a management buy-in of Baulkham Hills, New South Wales-based Global Orthopaedic in 2014. The company is Australia’s largest sovereign product orthopaedic business, which designs, manufactures and distributes a portfolio of hip and knee implants, supported by adjunct products and technologies. During its hold, Riverside worked with Global Orthopaedic’s management to restructure the business by investing heavily in the hip and knee product portfolio, divesting non-core businesses, restructuring sales and distribution channels and expanding the talent pool. The business’s strong growth trajectory is underpinned by exciting project initiatives, such as Global Orthopaedic’s R&D collaboration with a group of leading Australian universities in the area of nanostructured surfaces as a potential solution to help fight joint replacement infection. Working with Riverside Partner Steven Spiteri on the investment for Riverside were Partners Simon Feiglin and Stuart Baxter, and Senior Associate Kevin Xu. Allier Capital provided corporate and strategic advice for Global Orthopaedic on the transaction. Herbert Smith Freehills guided the legal process. KPMG and Deloitte provided financial and tax advisement.
